75/100
✓ Peer-reviewed
alzhub usefulness score 75 out of 100.
·
JAMA neurology
·
2017-05-01
Among 193 cognitively healthy controls, 197 patients with mild cognitive impairment, and 180 patients with AD with dementia, plasma NFL correlated with CSF NFL (Spearman ρ = 0.59, P Conclusions and relevance Plasma NFL is associated with AD diagnosis and with cognitive, biochemical, and imaging hallmarks of the disease. 3 key findings →
Design: case-control study
Participants: 197
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
73/100
✓ Peer-reviewed
alzhub usefulness score 73 out of 100.
·
JAMA
·
2017-06-01
Among the 445 participants (243 with normal amyloid, 202 with elevated amyloid), mean (SD) age was 74.0 (5.9) years, mean education was 16.4 (2.7) years, and 52% were women. 2 key findings →
Design: longitudinal study
Participants: 243
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Cerebral accumulation of amyloid-β is thought to be the starting mechanism in Alzheimer's disease. 4 key findings →
Design: longitudinal study
Participants: 437
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
71/100
✓ Peer-reviewed
alzhub usefulness score 71 out of 100.
·
Nature medicine
·
2021-05-24
A combination of plasma phospho-tau (P-tau) and other accessible biomarkers might provide accurate prediction about the risk of developing Alzheimer's disease (AD) dementia. 2 key findings →
Participants: 340
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
For early detection of Alzheimer's disease, it is important to find biomarkers with predictive value for disease progression and clinical manifestations, such as cognitive decline. 1 key finding →
Design: longitudinal study
Participants: 282
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
65/100
✓ Peer-reviewed
alzhub usefulness score 65 out of 100.
·
BMC geriatrics
·
2015-09-07
MoCA and MMSE were more similar for dementia cases, but MoCA distributes MCI cases across a broader score range with less ceiling effect. 4 key findings →
Design: cross-sectional
Participants: 219
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
60/100
✓ Peer-reviewed
alzhub usefulness score 60 out of 100.
·
JAMA neurology
·
2020-07-01
The genotype KL-VSHET+ is associated with reduced AD risk and Aβ burden in individuals who are aged 60 to 80 years, cognitively normal, and carrying APOE4. 5 key findings →
Design: case-control study
Participants: 20
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
60/100
✓ Peer-reviewed
alzhub usefulness score 60 out of 100.
·
JAMA neurology
·
2015-05-01
Vascular endothelial growth factor was associated with baseline hippocampal volume (t277 = 2.62; P = .009), longitudinal hippocampal atrophy (t858 = 2.48; P = .01), and longitudinal decline in memory (t1629 = 4.09; P Conclusions and relevance Elevated cerebrospinal fluid VEGF was associated with more optimal brain aging in vivo. 4 key findings →
Design: longitudinal study
Participants: 90
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
To assess plasma phosphorylated tau181 (p-tau181) as a progression biomarker in Alzheimer's disease (AD), we examined longitudinal plasma p-tau181 of 1184 participants (403 cognitively normal (CN), 560 patients with mild cognitive impairment (MCI), and 221 with AD dementia) from Alzheimer's Disease Neuroimaging Initiative (ADNI). 4 key findings →
Design: longitudinal study
Participants: 1,184
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
The relationship between mild behavioral impairment (MBI) and Alzheimer's disease (AD) is intricate and still not well investigated. 4 key findings →
Design: longitudinal study
Participants: 1,129
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Structural magnetic resonance imaging data are frequently analysed to reveal morphological changes of the human brain in dementia. 3 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Amyloid deposition and neurofibrillary degeneration in Alzheimer's disease specifically affect discrete neuronal systems, but the underlying mechanisms that render some brain regions more vulnerable to Alzheimer's disease pathology than others remain largely unknown. 4 key findings →
Participants: 76
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
59/100
✓ Peer-reviewed
alzhub usefulness score 59 out of 100.
·
JAMA network open
·
2019-12-02
Identifying brain regions associated with risk factors for dementia could guide mechanistic understanding of risk factors associated with Alzheimer disease (AD). 4 key findings →
Design: cross-sectional
Participants: 8,312
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
58/100
✓ Peer-reviewed
alzhub usefulness score 58 out of 100.
·
JAMA neurology
·
2015-12-14
A reliable method of detecting Alzheimer disease (AD) in its prodromal state is needed for patient stratification in clinical trials or for personalizing existing or potential upcoming therapies. 4 key findings →
Design: cohort study
Participants: 928
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
We analyzed data from 462 ADNI participants without dementia who underwent Aβ ([ 18 F]florbetapir or [ 18 F]florbetaben) and tau ([ 18 F]flortaucipir) PET, structural MRI, and cognitive testing. 4 key findings →
Design: cross-sectional
Participants: 156
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Less-invasive biomarkers for early Alzheimer disease (AD) are urgently needed. 3 key findings →
Design: randomized controlled trial
Participants: 109
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
57/100
✓ Peer-reviewed
alzhub usefulness score 57 out of 100.
·
PloS one
·
2012-08-02
Age is the strongest risk factor for sporadic Alzheimer disease (AD), yet the effects of age on rates of clinical decline and brain atrophy in AD have been largely unexplored. 2 key findings →
Design: longitudinal study
Participants: 723
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
In sum, we present a diagnostic tool for MCI and AD trained using baseline scans and a follow-up diagnosis regardless of progression, which is multi-diagnostic, generalizable across independent data sources and acquisition protocols, and with transparently reported performance. 5 key findings →
Participants: 570
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Identification of individuals at high risk of dementia is essential for development of prevention strategies, but reliable tools are lacking for risk stratification in the population. 4 key findings →
Participants: 181
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
56/100
✓ Peer-reviewed
alzhub usefulness score 56 out of 100.
·
NeuroImage
·
2019-12-16
Alzheimer's disease (AD) is a progressive and irreversible brain degenerative disorder. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Education, occupation, premorbid intelligence, and brain size are surrogate markers for cognitive reserve. 1 key finding →
Design: longitudinal study
Participants: 819
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
55/100
✓ Peer-reviewed
alzhub usefulness score 55 out of 100.
·
Neurology
·
2021-12-22
Experimental studies suggest that the balance between short and long β-amyloid (Aβ) species might modulate the toxic effects of Aβ in Alzheimer disease (AD), but clinical evidence is lacking. 4 key findings →
Participants: 656
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
54/100
✓ Peer-reviewed
alzhub usefulness score 54 out of 100.
·
Aging
·
2019-05-01
Age-related hearing loss (ARHL) has been considered as a promising modifiable risk factor for cognitive impairment and dementia. 4 key findings →
Design: cross-sectional
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
54/100
✓ Peer-reviewed
alzhub usefulness score 54 out of 100.
·
NeuroImage
·
2019-07-22
Individuals with Alzheimer's disease (AD) dementia exhibit significant heterogeneity across clinical symptoms, atrophy patterns, and spatial distribution of Tau deposition. 4 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
MR analysis suggested a causal relationship between decreased blood-derived mtDNA-CN and increased risk of AD (OR = 0.68; P = 0.013). 5 key findings →
Participants: 13,799
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomized / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multicenter collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 34,180 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.